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Abstract
Background: Aerosol therapy in preterm infants is challenging, as a very small proportion of the drug deposits in
the lungs.
Aim: Our aim was to compare efficiency of standard devices with newer, more efficient aerosol delivery devices.
Methods: Using salbutamol as a drug marker, we studied two prototypes of the investigational eFlow nebu-
lizer for babies (PARI Pharma GmbH), a jet nebulizer (Intersurgical Cirrus), and a pressurized metered dose
inhaler (pMDI; GSK) with a detergent-coated holding chamber (AeroChamber MV) in the premature infant
nose throat-model (PrINT-model) of a 32-week preterm infant (1,750 g). A filter or an impactor was placed below
the infant model’s ‘‘trachea’’ to capture the drug dose or particle size, respectively, that would have been
deposited in the lung.
Results: Lung dose (percentage of nominal dose) was 1.5%, 6.8%, and 18.0–20.6% for the jet nebulizer, pMDI-
holding chamber, and investigational eFlow nebulizers, respectively ( p < 0.001). Jet nebulizer residue was 69.4%
and 10.7–13.9% for the investigational eFlow nebulizers ( p < 0.001). Adding an elbow extension between the
eFlow and the model significantly lowered lung dose ( p < 0.001). A breathing pattern with lower tidal volume
decreased deposition in the PrINT-model and device residue ( p < 0.05), but did not decrease lung dose.
Conclusions: In a model for infant aerosol inhalation, we confirmed low lung dose using jet nebulizers and
pMDI-holding chambers, whereas newer, more specialized vibrating membrane devices, designed specifically
for use in preterm infants, deliver up to 20 times more drug to the infant’s lung.
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Introduction
Aerosol therapy offers advantages in lung disease as thedrug is delivered directly to the target site with minimal
systemic adverse effects.1 However, delivering aerosolized
medication to preterm infants is challenging due to high inter-
and intrapatient variability, lack of cooperation, small air-
ways, low tidal volumes, and short respiratory cycles with a
high breathing frequency, leading to low lung deposition.
Few aerosol devices have been developed specifically for this
patient group.2,3 Previous studies performed in in vitro and
animal lung models and in human infants have demon-
strated consistently low pulmonary deposition with standard
delivery devices [jet nebulizers or pressurized metered dose
inhalers (pMDIs)], whether the patient is breathing sponta-
neously, being intubated, or receiving noninvasive ventila-
tory support such as continuous positive airway pressure.4–6
In the case of bronchodilators, low lung deposition in
preterm infants might be sufficient, particularly when cor-
rected for body weight. Fok et al. showed that nebulization
with standard devices results in a clinical response,7 but
optimal dosage per kilogram of body weight—per nebulizer
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type—is still unclear.8 Optimizing nebulizer efficiency might
offer new therapeutic options. Use of newer technology has
been shown to achieve higher lung delivery efficiency in
ventilated macaques (up to > 14% with vibrating membrane
nebulizers),9 but thus far this has not been shown in spon-
taneously breathing infants. In adults, lung deposition with
an investigational PARI eFlow (including a small valved
holding chamber) was 38 – 4.3% (mean– SD) of nebulizer
charge.10
Important factors influencing lung deposition are the
particle size produced by the device, mechanical dead space,
residual volume, and, for jet nebulizers, flow requirements.
Also, a non-tightly fitted face mask greatly reduces drug
delivery to the patient.11,12
In this study, we evaluated lung deposition of salbutamol
as a drug marker using a standard jet nebulizer (Inter-
surgical Cirrus), a pMDI (GSK) with a detergent-coated
holding chamber (AeroChamber MV), and two vibrating
membrane nebulizers (PARI Pharma’s investigational eFlow
nebulizer prototypes for babies) simulating two clinical
conditions by applying different breathing patterns. To fa-
cilitate clinical use, two elbow extensions positioned between
the model and the eFlow nebulizer were tested.
Methods and Materials
Upper airway model
The premature infant nose throat-model (PrINT-model) is
described extensively elsewhere.13 In short, this upper air-
way model corresponding to a premature infant of 32-weeks
gestational age (1,750 g) was developed from a three-planar
magnetic resonance imaging scan. It was constructed using
three-dimensional printing and a photopolymer (FullCure
720) and validated by comparison of total airway volume
with a high-resolution computed tomography scan. The
model includes the upper airways from the nostrils down to
4mm below the vocal cords, and the mouth is closed. With a
corresponding breathing pattern, the model has proved to be
valuable in assessing aerosol delivery.13
Devices and face masks
A standard jet nebulizer [Intersurgical Cirrus, Berkshire,
UK; 3.5 lm volume median diameter (VMD)] with a bottom-
loaded vented infant face mask (Unomedical) was evalu-
ated and compared with a pMDI (Allen & Hanburys, GSK,
Middlesex, UK) with a detergent-coated holding chamber
without valve (AeroChamber MV) and Laerdal infant
mask (unvented). In addition, two vibrating membrane
nebulizers were tested, both with a front-loaded PARI
SmartMask Baby mask (vented): the prototype investiga-
tional eFlow nebulizers for babies, one with a small
(eFlowSR) and one with a large (eFlowLR) reservoir (PARI
Pharma GmbH, Munich, Germany; 3.0 lm VMD). The size
of the laser-drilled holes in the aerosol generator (vibrating
membrane) of the eFlow devices determines the particle
size of the aerosol. The investigational nebulizers are de-
signed to have a low residual volume.
The jet nebulizer was run at 6 L/min until at least 30 sec
after sputtering commenced. The pMDI canister (Ventolin,
100 lg per actuation) was shaken for 15 sec and attached to
the holding chamber after five waste actuations. The ratio of
actuation/breaths was 1:10, and actuation cycles were re-
peated five times [nominal dose (ND) 500 lg]. Between cy-
cles, the canister and actuator were shaken again for 5 sec.
The vibrating membrane devices were run continuously
until nebulization stopped.
Using the eFlowSR, two different elbows with a corner of
45 and 90 (to optimize the angle between patient and
nebulizer to facilitate clinical use) were compared with no
elbow.
Experimental setup
Face masks with attached nebulizer were fitted tightly
to the PrINT-model using Parafilm (Brand GmbH, Wer-
theim, Germany). The vents in the face masks were not
covered. The airway model was attached to a modified
22-mm T-piece below the tracheal opening to create an
additional dead space of 2.2mL on top of 1.3 mL dead
space from the airway model. Total dead space was 3.5mL,
corresponding to the airway dead space in infants weighing
1,750 g. In setup A (Fig. 1A), a filter was attached to the
T-piece to measure lung dose (LD); in setup B (Fig. 1B), the
filter was replaced by a Next Generation Impactor in
order to measure particle size at the tracheal opening of the
airway model.
Both the filter and the impactor setups were performed
using a constant flow through the system commonly used in
impactor measurements. In all setups, the air flow through
the filter and the impactor was kept constant at 15 L/min
using a suction device and a mass flow controller (Analyt-
MTC, Modell GFC, Mu¨llheim, Germany). This flow was in-
dependent from any driving flow of a nebulizer, as the
nebulizer was attached to the model and not included in the
circuit. Aerosols that were actively inhaled through the air-
way model entered this constant flow circuit. A zero flow at
the tracheal opening of the PrINT-model was balanced by
applying a regulated blowing airflow of 15L/min to the side
port of the T-piece (Fig. 1). Humidity and temperature were
kept constant at 50% relative humidity (– 3%) and 23C
(– 1C). To prevent dripping of collected drug from the up-
per airways onto the filter, the setup was turned upside
down (this was not possible using the jet nebulizer with
bottom-loaded face mask and when performing the particle
size measurements with impactor for the jet nebulizer and
the prototype investigational eFlow nebulizer). The impactor
was cooled to prevent evaporation.
Nebulizer, elbow, PrINT-model, modified T-piece, and
(lung) filter were washed separately with 22.5mL of meth-
anol. A total of 2.5mL of NaOH (0.1mol/L) was added to
each wash, and subsequently absorbance of salbutamol was
measured with a spectrophotometric method (Shimadzu
UV-1601; Shimadzu, Kyoto, Japan; wavelength 276 nm). All
face masks were excluded from drug analysis due to leach-
ing of softeners and colors when washed in methanol, which
interfered with the absorbance measurements.
All experiments were repeated six times.
Definitions
Total output rate has been calculated from the weight
difference of the nebulizer before and after nebulization.
Lung dose (LD) was drug deposition in the filter or impactor
including deposition in the T-piece. Drug deposition on the
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PrINT-model (PD) was determined separately for deposition
on the face (FD) and deposition on the inner airways of the
model (AD). Inhaled mass (IM) was defined as LD plus PD.
Device residue (DR) was determined including deposition in
the elbow, as the output of the device was defined as amount
of aerosol available for inhalation at the face mask. All values
were expressed as a percentage of ND, with ND defined as
total amount of drug filled in the device. Values were also
calculated as a percentage of emitted dose (ED; total amount
of drug exiting the device).
Breathing patterns
Two different breathing patterns were used (Harvard
Rodent Ventilator, Model 683, Harvard Apparatus, Holliston,
MA): (1) a ‘‘high’’ breathing pattern (HBP) with a tidal
volume of 12mL and a respiratory rate of 80 breaths per
minute (bpm) resembling an infant in distress; and (2) a
‘‘low’’ breathing pattern (LBP; tidal volume of 8.75mL and
frequency of 60 bpm), which reflects a physiologic breathing
pattern of a quiet infant.
FIG. 1. Experimental setup (A) to measure lung deposition, device residue, and deposition in the PrINT-model; and (B) to
measure particle size distribution of lung dose during simulated inhalation.
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Statistical analysis
DR, LD, and PD were compared using one-way analysis
of variance ( p < 0.05). Subsequently, if significance was
present, comparisons were made for each pair of means. As
we compared four devices, six pairwise comparisons were
made using Bonferroni’s correction for multiple testing with
significance level p= 0.008 (0.05/6), and three pairwise
comparisons for the three elbow setups with p= 0.017
(0.05/3). Independent-samples t tests were used to compare
the difference in deposition variables between the two
breathing patterns and deposition in the two elbows.
The correlation between DR and PD or LD was investi-
gated using Pearson’s correlation coefficients (SPSS Statistics,
17.0; SPSS, Chicago, IL).
Results
Four aerosol delivery devices
LD was significantly lower for the jet nebulizer [1.5% of
ND (0.2), mean (SD)] and pMDI-holding chamber [6.8%
(1.0)] compared with the investigational eFlow nebulizers
with small and large reservoir: 18.0% (1.7) and 20.6% (1.8),
respectively ( p< 0.001; Fig. 2). In all experiments, higher DR
was strongly correlated with lower LD (r= –0.98, p< 0.01)
and lower PD (r= - 0.98, p< 0.01). LD and PD were posi-
tively correlated (r= 0.98, p< 0.01). Analysis of all experi-
ments using the ED gave similar results.
Breathing patterns
An LBP (reflecting physiological quiet tidal breathing) de-
creased PD (p<0.05). However, it did not decrease LD (Fig. 3A),
and DR was only significantly affected for the jet nebulizer and
the membrane nebulizer with elbow (Fig. 3B). Details for
deposition as a percentage of the ND are presented in Table 1.
Elbow experiments
Adding an elbow extension to the membrane nebulizer
did decrease LD (Fig. 4). The corner of 90 in the elbow even
further decreased IM compared with the 45 elbow
( p < 0.001). Deposition in the 45 elbow itself was 13.3% of
ND (1.1) versus 15.7% (2.7) in the 90 elbow ( p= 0.09). The
90 elbow had two small vents, which were closed with
Parafilm in three additional runs. This did not have an effect
on LD [open 7.3% (1.7) and closed 7.6% (0.7)] and PD [11.2%
(1.1) to 12.4% (0.2)].
Aerosol particle size
The particle size characteristics of the aerosol exiting the
infant model (i.e., entering the infant’s ‘‘lungs’’) are summa-
rized for two devices in Table 2.
FIG. 2. LD, DR, and PD for four aerosol devices. IM is PD
plus LD. Data represent means + SD and are expressed as a
percentage of ND. The HBP was applied. All differences
between devices are significant ( p< 0.001), except differences
in PD and DR between eFlowSR and eFlowLR, and the dif-
ference in LD is p = 0.023.
FIG. 3. (A) LD and (B) DR comparing two breathing pat-
terns in three nebulizers. Data for eFlowSR with the attached
45 elbow are presented to show difference compared with
eFlow without elbow. Results for eFlowLR and eFlowSR are
comparable (see Fig. 2). DR includes residual drug in the
elbow. Data represent means + SD (% of ND). *p < 0.05 HBP
vs. LBP.
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Face deposition
Between 2.4% and 21.4% of the ED was deposited on the
face (FD) of the PrINT-model (Table 1). For the jet nebulizer,
the ratio between AD and FD was 1:1. For the eFlow nebu-
lizers, FD was two to four times as much as AD.
Discussion
This study compared several aerosol delivery devices in
an upper airway model of a preterm infant. All experiments
were done under similar flow, pressure, and humidity set-
tings. Two different breathing patterns were applied, and an
adequate amount of dead space was simulated. We found
lung deposition was considerably higher for customized vi-
brating membrane nebulizers (between 18.0% and 20.5% of
ND), compared with a commonly used jet nebulizer and
pMDI (1.5% and 6.8%, respectively). Previously published
in vivo deposition studies of inhaled radiolabeled salbutamol
demonstrated lung deposition in spontaneously breathing
infants with bronchopulmonary dyplasia ranging from
0.12% to 2.26% for an MDI and from 0.12% to 0.66% for a jet
nebulizer.6 Cumulative urine excretion of nebulized sodium
cromoglycate in ex-preterm infants’ pulmonary deposition
was estimated to be between 0.46% and 0.89% of ND for
different nebulizers.14 In our study, lung deposition using
the pMDI and jet nebulizer was comparable, but higher,
probably due to optimization of study conditions (i.e., no air
leaks in the face mask, no simulation of impaired patient
cooperation such as struggling and crying, stable and opti-
mal temperature and humidity conditions).
In vitro models are useful tools in studying aerosol deliv-
ery in preterm infants.4,13 They are well correlated to in vivo
performance15 and help minimize radiolabeled aerosol de-
position studies in animals and humans, which require
special ethical considerations.16 However, in vitro filter set-
ups tend to overestimate aerosol delivery because of the
absolute nature of filters, which cannot simulate possible loss
of aerosol during exhalation.
Two important factors that influence aerosol delivery
(besides aerosol particle size, ventilating parameters, and
patient-related factors) are nebulizer efficiency and aerosol
density. Dubus et al. demonstrated that higher nebulizer ef-
ficiency is due mainly to the lower residual volume of newer
vibrating membrane devices.9 We confirmed those findings
in our study: lower nebulizer residue was strongly correlated
with higher lung deposition. Furthermore, less drug residue
and reduced ND needed are potentially cost-saving factors,
especially if expensive drugs are considered. As an addi-
tional benefit, the higher efficiency of vibrating membrane
devices was combined with shorter treatment times. The
output rate of the investigational eFlowSR was almost dou-
ble that of the jet nebulizer (238mg/min vs. 117mg/min).
This might be beneficial particularly in infants and children,
where cooperation is essential. It has been suggested that
inhaled therapy should be performed during quiet sleep,17
and the vibrating membrane devices do combine short
treatment times with silent operation.
Despite the multiple advantages of the vibrating mem-
brane nebulizers, it must be remembered that the high
Table 1. Deposition of Salbutamol Aerosol on PrINT-Model and Lung Filter for Two
Breathing Patterns as Percentage of Nominal Dose
Delivery device Breathing pattern Lung dose (% ND) PrINT deposition (% ND)
Jet nebulizer High 1.5 (0.2) 2.4 (0.6)
Face: 1.2 (0.4) Airway: 1.2 (0.5)
Low 1.2 (0.6) 1.5 (0.6)
eFlowSR High 18.0 (1.7) 26.5 (0.8)
eFlowSR, 45 elbow High 12.6 (0.9) 19.9 (1.3)
Low 13.8 (1.7) 11.9 (1.7)
eFlowSR, 90 elbow High 7.3 (1.7) 11.2 (1.1)
eFlowLR High 20.6 (1.8) 26.7 (2.5)
Face: 19.4 (3.7) Airway: 8.5 (5.7)
Low 21.6 (1.4) 16.5 (1.4)
Face: 13.0 (2.6) Airway: 3.4 (1.4)
pMDI High 6.8 (1.0) 8.4 (0.5)
See also Figure 2. Analysis using the ED gave similar results.
FIG. 4. LD, DR, and PD applying two types of elbow ex-
tensions attached to the eFlowSR. DR includes residual drug
in the elbow. Data represent means + SD and are expressed
as a percentage of ND. The HBP was applied. All differences
are significant ( p < 0.001), except DR for elbow 45 and 90.
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efficiency of these devices may lead to potential overdosing
or other side effects. Currently, it remains unclear if the eight
to 10 times higher aerosol deposition on the model’s airway,
in addition to a higher deposition on the face compared with
the jet nebulizer, leads to an increased risk of dose-related
adverse effects, depending on the drug being delivered. The
setup used in these experiments was not able to answer these
questions. For jet nebulizer use in preterm infants, we con-
firmed that the amount of drug inhaled depends more on its
driving flow than on its tidal volume. In our setup, the HBP
resulted in a minute ventilation of 790mL/min when mea-
sured at the nostrils, and the LBP in a ventilation of 480mL/
min. The driving flow of the nebulizer was 6L/min, so at
least five-sixths of the aerosolized drug cannot be inhaled in
aroused preterm infants with a higher breathing pattern. The
LBP simulates quiet tidal breathing in a preterm infant, and
here more than 90% of the aerosol is lost through the holes in
the mask. For the jet nebulizer, we demonstrated that 70% of
the initial dose is left in the reservoir, so theoretically only 3%
of the initial dose is available for inhalation (i.e., only 30%
exits the nebulizer, and of that only 10% can be inhaled).
Smaldone et al. showed that IM (drug delivery at the mouth
orifice of a face model of a 2-year-old child) using a jet
nebulizer operated at 8 L/min was 50% lower than when the
nebulizer was operated at 4 L/min.12 This reflects the dis-
proportion of minute ventilation and the amount of air in
which the aerosol is dispersed (aerosol density). Once in-
spiratory flow is greater than the driving gas flow, the
aerosol is diluted by entrained air. In preterm infants, this
effect does not occur, and therefore they inhale a much larger
dose in dose per kilogram than adults.18,19
Due to an entirely different operating technique, the
pMDI-holding chamber is more effective than the jet nebu-
lizer, but with its higher device (holding chamber) residue,
lung deposition is lower than for the vibrating membrane
devices. The latter devices operate without a driving flow,
but merely create an undiluted cloud of a highly concen-
trated aerosol in front of the preterm infant’s nose, which can
be readily inhaled. For the clinical setting, where costs are an
important factor, the use of vibrating membrane nebulizers
has to be analyzed also by a cost-effect and side-effect
analysis. We propose a detailed analysis for different specific
clinical settings; in our experiment, we used salbutamol only
as a drug marker, and we did not intend to perform any
form of cost analysis.
In conclusion, the jet nebulizer and pMDI-holding cham-
ber are less efficient in aerosol delivery compared with newer
vibrating membrane devices in an in vitromodel of a preterm
infant of 32-weeks gestational age. This is due to a high
driving flow in relation to the minute ventilation, a higher
nebulizer residue, and the technique of a driving flow
opposed to an almost standing cloud of a highly concen-
trated aerosol from a vibrating membrane. A possible clinical
consequence of our study might be that, in using the tradi-
tional devices, higher doses are needed to get the desired
effect. Also, as lung deposition may be reduced in the clinical
setting, in vivo clinical studies are necessary to confirm the
deposition measurements from vibrating membrane nebu-
lizers shown in this study.
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